Business Description
Dechra Pharmaceuticals PLC
ISIN : GB0009633180
Share Class Description:
MEX:DPH: Ordinary SharesDescription
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.15 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | 5.17 | |||||
| Interest Coverage | 0.14 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.05 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.3 | |||||
| 3-Year EBITDA Growth Rate | -10.2 | |||||
| 3-Year EPS without NRI Growth Rate | 0.9 | |||||
| 3-Year FCF Growth Rate | -19.2 | |||||
| 3-Year Book Growth Rate | 4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 11.91 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.85 | |||||
| Quick Ratio | 1.53 | |||||
| Cash Ratio | 0.45 | |||||
| Days Inventory | 223.88 | |||||
| Days Sales Outstanding | 62.66 | |||||
| Days Payable | 83.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.49 | |||||
| 3-Year Dividend Growth Rate | 11.9 | |||||
| 3-Year Average Share Buyback Ratio | -1.8 | |||||
| Shareholder Yield % | -8.01 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.98 | |||||
| Operating Margin % | 0.83 | |||||
| Net Margin % | -3.66 | |||||
| FCF Margin % | 4.63 | |||||
| ROE % | -3.7 | |||||
| ROA % | -1.82 | |||||
| ROIC % | 0.36 | |||||
| ROC (Joel Greenblatt) % | 2.36 | |||||
| ROCE % | 0.57 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 40.91 | |||||
| Shiller PE Ratio | 101.55 | |||||
| PEG Ratio | 13.2 | |||||
| PS Ratio | 5.79 | |||||
| PB Ratio | 5.83 | |||||
| Price-to-Free-Cash-Flow | 131.95 | |||||
| Price-to-Operating-Cash-Flow | 69.28 | |||||
| EV-to-EBIT | 619.41 | |||||
| EV-to-Forward-EBIT | 35.85 | |||||
| EV-to-EBITDA | 49.55 | |||||
| EV-to-Revenue | 6.34 | |||||
| EV-to-Forward-Revenue | 4.04 | |||||
| EV-to-FCF | 145.09 | |||||
| Price-to-Projected-FCF | 4.07 | |||||
| Price-to-DCF (Earnings Based) | 1.74 | |||||
| Price-to-DCF (FCF Based) | 10.51 | |||||
| Price-to-Median-PS-Value | 1.03 | |||||
| Earnings Yield (Greenblatt) % | 0.16 | |||||
| FCF Yield % | 0.76 | |||||
| Forward Rate of Return (Yacktman) % | 3.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dechra Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 17,377.9 | ||
| EPS (TTM) (MXN) | -4.957 | ||
| Beta | 0 | ||
| Volatility % | 0.31 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 858.69 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 858.69 - 858.69 | ||
| Shares Outstanding (Mil) | 113.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dechra Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dechra Pharmaceuticals PLC Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dechra Pharmaceuticals PLC Frequently Asked Questions
What is Dechra Pharmaceuticals PLC(MEX:DPH)'s stock price today?
The current price of MEX:DPH is MXN858.69. The 52 week high of MEX:DPH is MXN858.69 and 52 week low is MXN858.69.
When is next earnings date of Dechra Pharmaceuticals PLC(MEX:DPH)?
The next earnings date of Dechra Pharmaceuticals PLC(MEX:DPH) is 2024-10-11 Est..
Does Dechra Pharmaceuticals PLC(MEX:DPH) pay dividends? If so, how much?
Dechra Pharmaceuticals PLC(MEX:DPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers